Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.
Tokai Pharmaceuticals, Inc. Key Developments
Tokai Pharmaceuticals, Inc. Appoints Lee Kalowski as Chief Financial Officer
Sep 2 14
Tokai Pharmaceuticals, Inc. announced the appointment of Lee Kalowski as chief financial officer, effective immediately. Mr. Kalowski brings more than a decade of experience in the life sciences sector to Tokai. Prior to joining Tokai, Mr. Kalowski served as vice president, global biotechnology equity research at Credit Suisse. Prior to joining Credit Suisse, he worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group.
Tokai Pharmaceuticals Appoints Daniel T. Dransfield as Vice President, Head of Translational Medicine
Aug 27 14
Tokai Pharmaceuticals, Inc. announced the appointment of Daniel T. Dransfield, Ph.D. as vice president and head of translational medicine. Dr. Dransfield, formerly vice president of discovery research and translational medicine at ArQule, Inc., brings more than 20 years of drug development and research experience to Tokai. At ArQule, Dr. Dransfield held vice president positions in discovery research, translational medicine and kinase biology since 2012, where he supervised multiple teams of scientists that evaluated therapeutic candidates, shaping the company's clinical programs and development strategy. Prior to his positions at ArQule, Dr. Dransfield spent 11 years at Dyax Corporation in roles of increasing responsibility, culminating as vice president of cell biology and translational research. Prior to Dyax, he worked for nearly a decade in various instructor and scientist roles at the Institute of Molecular Medicine & Genetics, Medical College of Georgia.
Tokai Pharmaceuticals, Inc. Announces Positive Interim Results from the Phase 2 ARMOR2 Study of Galeterone Among Patients
Jun 2 14
Tokai Pharmaceuticals, Inc. announced positive interim results from the Phase 2 ARMOR2 study of galeterone among patients with castration-resistant prostate cancer. These data demonstrated clinically meaningful reductions in prostate-specific androgen levels, a marker of prostate cancer growth. The data were presented on May 31, in a poster presentation by Bruce Montgomery, M.D., Professor, Medical Oncology Division, University of Washington School of Medicine, and a lead investigator of the ARMOR2 trial, at the American Society of Clinical Oncology 2014 annual meeting in Chicago. The ongoing ARMOR2 trial is a two-part Phase 2 study designed to confirm the dose of galeterone and demonstrate safety and efficacy in distinct CRPC patient cohorts. Part 2 is also screening for AR mutations and splice variants, including AR-V7, based on preclinical data showing galeterone activity in this setting. Approximately 132 patients are expected to be enrolled in Part 2 of the trial. At the conclusion of Part 1 of the study, a once-daily galeterone dose of 2,550 mg was selected for Part 2 based upon review of safety, efficacy and pharmacokinetic data. Interim results include data on 87 patients in Part 1 and Part 2 of the trial who were treated with galeterone at a daily dose of 2,550 mg. Among 51 treatment-naïve CRPC patients, 82% achieved a maximal reduction in PSA levels of at least 30% and 75% achieved a maximal reduction in PSA levels of at least 50%. Among treatment-naïve patients with metastatic CRPC, interim data in 39 patients show that 85% achieved a PSA30 and 77% achieved a PSA50. Among 15 abiraterone-refractory patients, 27% had a PSA decline.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|